Gilmore Neil O'Neill

CIK: 0001742084

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)9 (75.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (25.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

EDIT

Editas Medicine, Inc.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (12 total)

EDIT
Editas Medicine, Inc.
Sep 3, 2026
Sale(S)
Direct
5.1K shares at avg. $3.04$16K
EDIT
Editas Medicine, Inc.
Jun 3, 2026
Sale(S)
Direct
15.4K shares at avg. $2.70$42K
EDIT
Editas Medicine, Inc.
Mar 12, 2026
Award(A)
Stock Option (right to buy)
Direct
1M shares-
EDIT
Editas Medicine, Inc.
Mar 3, 2026
Sale(S)
Direct
5.4K shares at avg. $2.02$11K
EDIT
Editas Medicine, Inc.
Dec 3, 2025
Sale(S)
Direct
5.6K shares at avg. $2.15$12K
EDIT
Editas Medicine, Inc.
Sep 3, 2025
Sale(S)
Direct
5.6K shares at avg. $2.60$15K
EDIT
Editas Medicine, Inc.
Jun 3, 2025
Sale(S)
Direct
15.2K shares at avg. $1.72$26K
EDIT
Editas Medicine, Inc.
Mar 8, 2025
Award(A)
Stock Option (right to buy)
Direct
828K shares-
EDIT
Editas Medicine, Inc.
Mar 8, 2025
Award(A)
Stock Option (right to buy)
Direct
175K shares-
EDIT
Editas Medicine, Inc.
Mar 4, 2025
Sale(S)
Direct
16.6K shares at avg. $1.71$28K
EDIT
Editas Medicine, Inc.
Dec 3, 2024
Sale(S)
Direct
1.6K shares at avg. $2.08$3K
EDIT
Editas Medicine, Inc.
Sep 4, 2024
Sale(S)
Direct
1.6K shares at avg. $3.42$5K

		Type	Shares	Price		Ownership
Sep 3, 2026	EDIT Editas Medicine, Inc.	Sale(S)	5,124	$3.04	$15,563	Direct
Jun 3, 2026	EDIT Editas Medicine, Inc.	Sale(S)	15,380	$2.70	$41,543	Direct
Mar 12, 2026	EDIT Editas Medicine, Inc.	Award(A) Stock Option (right to buy)	1,015,200	-	-	Direct
Mar 3, 2026	EDIT Editas Medicine, Inc.	Sale(S)	5,394	$2.02	$10,894	Direct
Dec 3, 2025	EDIT Editas Medicine, Inc.	Sale(S)	5,603	$2.15	$12,064	Direct
Sep 3, 2025	EDIT Editas Medicine, Inc.	Sale(S)	5,592	$2.60	$14,517	Direct
Jun 3, 2025	EDIT Editas Medicine, Inc.	Sale(S)	15,192	$1.72	$26,196	Direct
Mar 8, 2025	EDIT Editas Medicine, Inc.	Award(A) Stock Option (right to buy)	828,000	-	-	Direct
Mar 8, 2025	EDIT Editas Medicine, Inc.	Award(A) Stock Option (right to buy)	175,000	-	-	Direct
Mar 4, 2025	EDIT Editas Medicine, Inc.	Sale(S)	16,632	$1.71	$28,452	Direct
Dec 3, 2024	EDIT Editas Medicine, Inc.	Sale(S)	1,618	$2.08	$3,361	Direct
Sep 4, 2024	EDIT Editas Medicine, Inc.	Sale(S)	1,555	$3.42	$5,325	Direct

1-12 of 12 transactions

About O'Neill Gilmore Neil

O'Neill Gilmore Neil (SEC CIK 0001742084) files insider reports with the SEC as CEO of Editas Medicine, Inc. (EDIT).

Signal8 holds 11 ownership filings by O'Neill Gilmore Neil, all Form 4s, filed between Sep 6, 2024 and Sep 4, 2026. Those filings report 12 transactions, from Sep 4, 2024 to Sep 3, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on O'Neill Gilmore Neil's filings is in CAMBRIDGE, MA.

Recent filings by O'Neill Gilmore Neil

Sep 3, 2026: Open-market sale of EDIT shares (Form 4, code S).
Jun 3, 2026: Open-market sale of EDIT shares (Form 4, code S).
Mar 12, 2026: Grant or award of EDIT derivative securities (Form 4, code A).
Mar 3, 2026: Open-market sale of EDIT shares (Form 4, code S).
Dec 3, 2025: Open-market sale of EDIT shares (Form 4, code S).

Other insiders filing for Editas Medicine, Inc. (EDIT)

Ory Daniel Scott, EVP, Chief Medical Officer
Burkly Linda, EVP, CHIEF SCIENTIFIC OFFICER
Parison Amy, SVP, Chief Financial Officer
Ellinor Patrick Thomas II, Director
Connaughton Bernadette, Director
Hopfield Jessica, Director

How to read Form 4 transaction codes